{"id":32306,"date":"2025-05-27T16:27:46","date_gmt":"2025-05-27T10:57:46","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32306"},"modified":"2025-07-31T13:02:59","modified_gmt":"2025-07-31T07:32:59","slug":"pharma-news-for-gilead-otsuka-liquidia","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia","title":{"rendered":"Gilead\u2019s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka\u2019s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK\u2019s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f2461c2c993\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f2461c2c993\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\/#Gileads_TRODELVY_Demonstrates_Significant_PFS_Benefit_in_First-Line_Metastatic_TNBC_in_ASCENT-03_Trial\" >Gilead\u2019s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\/#Otsukas_Sibeprenlimab_Receives_FDA_Priority_Review_for_IgA_Nephropathy\" >Otsuka\u2019s Sibeprenlimab Receives FDA Priority Review for IgA Nephropathy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\/#Liquidia_Secures_FDA_Approval_for_YUTREPIA_Inhalation_Powder_in_PAH_and_PH-ILD\" >Liquidia Secures FDA Approval for YUTREPIA Inhalation Powder in PAH and PH-ILD<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\/#GSKs_BLENREP_Combinations_Receive_Positive_CHMP_Opinion_for_RelapsedRefractory_Multiple_Myeloma\" >GSK\u2019s BLENREP Combinations Receive Positive CHMP Opinion for Relapsed\/Refractory Multiple Myeloma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\/#Relief_Therapeutics_Earns_FDA_Rare_Pediatric_Disease_Designation_for_RLF-TD011\" >Relief Therapeutics Earns FDA Rare Pediatric Disease Designation for RLF-TD011<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-gilead-s-trodelvy-demonstrates-significant-pfs-benefit-in-first-line-metastatic-tnbc-in-ascent-03-trial\"><span class=\"ez-toc-section\" id=\"Gileads_TRODELVY_Demonstrates_Significant_PFS_Benefit_in_First-Line_Metastatic_TNBC_in_ASCENT-03_Trial\"><\/span>Gilead\u2019s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Gilead Sciences<\/strong> has announced positive topline results from the<strong> Phase III ASCENT-03 trial<\/strong> of <strong>TRODELVY <\/strong>(sacituzumab govitecan-hziy) in <strong>first-line <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market\"><strong>metastatic triple-negative breast cancer (mTNBC)<\/strong><\/a> patients who are ineligible for PD-1\/PD-L1 inhibitor therapies. The study met its primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy. This is the first notable advance for this patient group in over two decades, underscoring TRODELVY\u2019s potential as a new standard of care.<\/p>\n\n\n\n<p>The safety profile of TRODELVY was consistent with previous studies, with no new safety signals reported. Overall survival, a secondary endpoint, was not mature at the time of analysis, though no negative impact was observed. Gilead plans further monitoring and will present detailed findings at a future medical meeting. Regulatory discussions are also planned as the company seeks potential approval for this new indication.<\/p>\n\n\n\n<p>The ASCENT-03 results follow the recent success of the ASCENT-04 trial, which evaluated TRODELVY in combination with KEYTRUDA in PD-L1+ mTNBC. Together, the trials suggest TRODELVY may be an effective foundational treatment across the full spectrum of first-line mTNBC. With four positive Phase III trials in HER2-negative metastatic breast cancer, TRODELVY remains the only approved Trop-2-directed antibody-drug conjugate (ADC) to show survival benefits across both mTNBC and HR+\/HER2- mBC.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cAlmost half of the patients diagnosed with metastatic triple-negative breast cancer do not receive treatment beyond first-line, demonstrating an urgent need for innovative treatment options in this early setting,\u201d said Dr. Javier Cortes, Head of the International Breast Cancer Center in Spain and principal investigator of the ASCENT-03 study. \u201cTraditional chemotherapy has been the standard of care, and we know that therapeutic advances in this disease area serve a critical unmet need.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe ASCENT-03 outcome represents the first clinically meaningful advance for this patient population in over 20 years versus chemotherapy,\u201d said Dr. Dietmar Berger, Chief Medical Officer, Gilead Sciences. \u201cBy addressing this aggressive and difficult-to-treat disease earlier, we can potentially improve treatment options for the high unmet need that patients with metastatic triple-negative breast cancer face.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-otsuka-s-sibeprenlimab-receives-fda-priority-review-for-iga-nephropathy\"><span class=\"ez-toc-section\" id=\"Otsukas_Sibeprenlimab_Receives_FDA_Priority_Review_for_IgA_Nephropathy\"><\/span>Otsuka\u2019s Sibeprenlimab Receives FDA Priority Review for IgA Nephropathy<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Otsuka Pharmaceutical<\/strong> and<strong> Otsuka Pharmaceutical Development &amp; Commercialization, Inc. (OPDC) <\/strong>announced that the <strong>FDA <\/strong>has accepted for review the <strong>Biologics License Application (BLA)<\/strong> for <strong>sibeprenlimab<\/strong>, an investigational monoclonal antibody that selectively inhibits APRIL (A PRoliferation-Inducing Ligand) for adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/iga-nephropathy-igan-market\"><strong>immunoglobulin A nephropathy (IgAN)<\/strong><\/a>. The BLA has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) target action date of November 28, 2025.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cOver the past decade, Otsuka has consistently approached difficult-to-treat diseases in nephrology with scientific and clinical innovation, seeking to provide crucial advancements for underserved patients with complex conditions like IgA nephropathy,\u201d said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development &amp; Commercialization, Inc. \u201cIf approved, sibeprenlimab would enable individuals living with IgA nephropathy to self-inject once every 4 weeks. We are thankful to share a potential treatment that could offer important clinical benefits and convenience to those living with this disease.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The BLA submission is supported by data from the Phase III VISIONARY trial (NCT05248646), which met its primary endpoint at the prespecified interim analysis, and the Phase II ENVISION trial (NCT04287985). In Phase III, sibeprenlimab showed a statistically significant and clinically meaningful reduction in 24-hour uPCR after nine months of treatment compared to placebo.<\/p>\n\n\n\n<p>Sibeprenlimab is designed for self-administration as a single-dose prefilled syringe for subcutaneous injection every four weeks. The therapy also holds Breakthrough Therapy designation based on Phase II results and offers a novel approach by targeting APRIL, a key driver in the 4-hit pathogenesis of IgAN that can lead to end-stage kidney disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-liquidia-secures-fda-approval-for-yutrepia-inhalation-powder-in-pah-and-ph-ild\"><span class=\"ez-toc-section\" id=\"Liquidia_Secures_FDA_Approval_for_YUTREPIA_Inhalation_Powder_in_PAH_and_PH-ILD\"><\/span>Liquidia Secures FDA Approval for YUTREPIA Inhalation Powder in PAH and PH-ILD<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Liquidia Corporation announced that the FDA has approved <strong>YUTREPIA (treprostinil) inhalation powder<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\"><strong>pulmonary arterial hypertension (PAH)<\/strong><\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market\"><strong>pulmonary hypertension associated with interstitial lung disease (PH-ILD)<\/strong><\/a> to improve exercise ability. YUTREPIA is the first and only dry-powder prostacyclin formulation enabled by Liquidia\u2019s proprietary PRINT\u2122 technology, engineered for deep-lung delivery using a portable, low-effort inhalation device.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday, we celebrate for the patients and physicians who will now have access to a potential best-in-class dry-powder form of treprostinil with exceptional portability, tolerability, titratability, and durability,\u201d said Dr. Roger Jeffs, CEO of Liquidia. \u201cThank you to the clinical investigation team, our steering committee, and the members of the pulmonary hypertension patient communities who helped make this day a reality. With today\u2019s milestone, our commercial team is prepared to launch YUTREPIA and bring meaningful change to the lives of patients in need, and we look forward to speaking with physicians and patients about the unique benefits of YUTREPIA in the days and weeks ahead.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>FDA approval was supported by results from the <strong>Phase III INSPIRE trial<\/strong>, which showed that YUTREPIA was safe and well-tolerated in both treprostinil-na\u00efve patients and those transitioning from nebulized formulations. Findings from the study have been published in the <em>Pulmonary Circulation<\/em> and <em>Vascular Pharmacology<\/em> journals. The inhalation powder provides a promising option for over <strong>105,000 patients in the U.S.<\/strong> living with PAH and PH-ILD.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cI am so pleased that patients with PAH and PH-ILD now have this newly introduced option for inhaled treprostinil,\u201d said Dr. Nicholas Hill, Chief of Pulmonary, Critical Care &amp; Sleep Division at Tufts University School of Medicine and Principal Investigator of the INSPIRE trial. \u201cHaving treated patients for more than six years in Liquidia\u2019s INSPIRE and extension studies, I am confident in the safety, tolerability, and dosing that YUTREPIA offers. The low-effort inhalation device used to deliver YUTREPIA may make it easier to start and maintain patients on treatment, especially those with limited inspiratory flows or lung capacity.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p><strong>Matt Granato<\/strong>, President and CEO of the Pulmonary Hypertension Association, also welcomed the news. He highlighted the significant burden of these conditions and the need for diverse therapeutic tools for physicians and patients alike.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPAH and PH-ILD impact more than 105,000 patients in the U.S. alone. These patient communities and the physicians who serve them need therapies that can lead to the improvement of quality of life,\u201d said Granato. \u201cWe are always glad to see industry research leading to the development of drugs that expand options for the patient community.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>However, legal uncertainty clouds the commercial rollout. United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, alleging that YUTREPIA infringes U.S. Patent No. 11,357,782 and requested a temporary restraining order and preliminary injunction to halt its commercialization. Oral arguments were heard on May 20, 2025, and the motion is currently pending in court.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gsk-s-blenrep-combinations-receive-positive-chmp-opinion-for-relapsed-refractory-multiple-myeloma\"><span class=\"ez-toc-section\" id=\"GSKs_BLENREP_Combinations_Receive_Positive_CHMP_Opinion_for_RelapsedRefractory_Multiple_Myeloma\"><\/span>GSK\u2019s BLENREP Combinations Receive Positive CHMP Opinion for Relapsed\/Refractory Multiple Myeloma<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In May 2025, <strong>GSK plc <\/strong>announced that the <strong>Committee for Medicinal Products for Human Use (CHMP)<\/strong> of the European Medicines Agency (EMA) has issued a <strong>positive opinion<\/strong> recommending the approval of <strong>BLENREP<\/strong> (belantamab mafodotin) for the treatment of adults with <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-myeloma-market\"><strong>relapsed or refractory multiple myeloma<\/strong><\/a>. The recommendation includes BLENREP in combination with bortezomib plus dexamethasone (BVd) for patients who have received at least one prior therapy, and with pomalidomide plus dexamethasone (BPd) for those previously treated with lenalidomide. A final decision by the European Commission is expected in Q3 2025.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cToday\u2019s positive CHMP opinion is an important milestone toward bringing the benefits of BLENREP combinations to patients with multiple myeloma in Europe,\u201d said <\/em><strong><em>Hesham Abdullah<\/em><\/strong><em>, Senior Vice President, Global Head Oncology, R&amp;D, GSK. \u201cBLENREP is well-positioned to address the unmet needs of these patients while also providing the benefit of in-office administration in both academic and community treatment settings without complex pre-administration regimens or hospitalization.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The CHMP opinion is backed by strong efficacy data from DREAMM-7 and DREAMM-8, two pivotal Phase III clinical trials. These studies demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to standard of care. DREAMM-7 also showed overall survival (OS) benefit against a daratumumab-based triplet regimen. Safety and tolerability profiles of BLENREP combinations remained consistent with those of the individual agents.<\/p>\n\n\n\n<p>There are around 50K new multiple myeloma cases diagnosed annually in Europe, and nearly all patients relapse after initial treatment. BLENREP is currently the only anti-BCMA antibody-drug conjugate (ADC) approved for this population, offering a differentiated mechanism of action. Its administration flexibility allows treatment across a wide range of oncology settings.<\/p>\n\n\n\n<p>BLENREP-related eye side effects observed in the trials were manageable and reversible with dose adjustments and monitoring, contributing to low discontinuation rates (\u22649%) in both studies. In DREAMM-7, common non-ocular adverse events included <strong>thrombocytopenia (87%) <\/strong>and <strong>diarrhoea (32%)<\/strong>, while<strong> neutropenia (63%),<\/strong> <strong>thrombocytopenia (55%),<\/strong> and <strong>COVID-19 (37%)<\/strong> were reported in DREAMM-8.<\/p>\n\n\n\n<p>BLENREP combinations are also under regulatory review in the U.S. (PDUFA date: July 23, 2025), China (with Breakthrough Therapy Designation and priority review), Canada, and Switzerland. If approved, these combinations could significantly expand treatment options for patients experiencing early relapse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-relief-therapeutics-earns-fda-rare-pediatric-disease-designation-for-rlf-td011\"><span class=\"ez-toc-section\" id=\"Relief_Therapeutics_Earns_FDA_Rare_Pediatric_Disease_Designation_for_RLF-TD011\"><\/span>Relief Therapeutics Earns FDA Rare Pediatric Disease Designation for RLF-TD011<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Relief Therapeutics Holding SA <\/strong>announced that the <strong>FDA<\/strong> has granted <strong>Rare Pediatric Disease (RPD) designation<\/strong> to its investigational therapy <strong>RLF-TD011<\/strong> for the treatment of <a href=\"https:\/\/www.delveinsight.com\/report-store\/epidermolysis-bullosa-market\"><strong>epidermolysis bullosa (EB)<\/strong><\/a>, a rare genetic disorder causing fragile skin and chronic wounds. The FDA had previously granted <strong>Orphan Drug Designation<\/strong> to RLF-TD011 for the same indication.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe FDA&#8217;s decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy,\u201d said <\/em><strong><em>Giorgio Reiner<\/em><\/strong><em>, Chief Scientific Officer of Relief. \u201cWe look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>RLF-TD011 is a hypotonic acid-oxidizing solution containing hypochlorous acid, engineered to offer potent antimicrobial and anti-inflammatory properties while supporting wound healing by maintaining a healthy microenvironment. Previous clinical findings have shown RLF-TD011\u2019s ability to reduce pathogenic colonization without harming beneficial bacteria, addressing key challenges in EB wound care.<\/p>\n\n\n\n<p>The Rare Pediatric Disease designation is granted to treatments targeting serious or life-threatening conditions affecting fewer than 200,000 individuals under age 18 in the U.S. Therapies that receive marketing approval under this designation may qualify for a Priority Review Voucher (PRV), a valuable asset that can expedite FDA review for another product. Notably, in <strong>May 2025<\/strong>, a PRV linked to a different EB treatment was <strong>sold for $155 million<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead\u2019s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial Gilead Sciences has announced positive topline results from the Phase III ASCENT-03 trial of TRODELVY (sacituzumab govitecan-hziy) in first-line metastatic triple-negative breast cancer (mTNBC) patients who are ineligible for PD-1\/PD-L1 inhibitor therapies. The study met its primary endpoint by showing a statistically [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":32307,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[204,16730,16726,704,22206,22235,349,410,420,639,499,17980,4067,5789,21321,19237],"industry":[17225],"therapeutic_areas":[17242,17237,17227,17228],"class_list":["post-32306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-delveinsight","tag-epidermolysis-bullosa","tag-epidermolysis-bullosa-market","tag-fda","tag-igan","tag-igan-treatment","tag-latest-pharma-news","tag-multiple-myeloma","tag-news","tag-pharma-news","tag-pulmonary-arterial-hypertension","tag-pulmonary-arterial-hypertension-drugs","tag-pulmonary-arterial-hypertension-market","tag-recent-pharma-news","tag-relapsed-or-refractory-multiple-myeloma","tag-triple-negative-breast-cancer-2","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Gilead, Otsuka, Liquidia<\/title>\n<meta name=\"description\" content=\"Gilead\u2019s TRODELVY; Otsuka\u2019s Sibeprenlimab; Liquidia\u2019s YUTREPIA; GSK\u2019s BLENREP; Relief Therapeutics\u2019 RLF-TD011.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Gilead, Otsuka, Liquidia\" \/>\n<meta property=\"og:description\" content=\"Gilead\u2019s TRODELVY; Otsuka\u2019s Sibeprenlimab; Liquidia\u2019s YUTREPIA; GSK\u2019s BLENREP; Relief Therapeutics\u2019 RLF-TD011.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T10:57:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-31T07:32:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Gilead, Otsuka, Liquidia","description":"Gilead\u2019s TRODELVY; Otsuka\u2019s Sibeprenlimab; Liquidia\u2019s YUTREPIA; GSK\u2019s BLENREP; Relief Therapeutics\u2019 RLF-TD011.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Gilead, Otsuka, Liquidia","og_description":"Gilead\u2019s TRODELVY; Otsuka\u2019s Sibeprenlimab; Liquidia\u2019s YUTREPIA; GSK\u2019s BLENREP; Relief Therapeutics\u2019 RLF-TD011.","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-05-27T10:57:46+00:00","article_modified_time":"2025-07-31T07:32:59+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia","name":"Pharma News | Gilead, Otsuka, Liquidia","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025.png","datePublished":"2025-05-27T10:57:46+00:00","dateModified":"2025-07-31T07:32:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Gilead\u2019s TRODELVY; Otsuka\u2019s Sibeprenlimab; Liquidia\u2019s YUTREPIA; GSK\u2019s BLENREP; Relief Therapeutics\u2019 RLF-TD011.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-gilead-otsuka-liquidia#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025.png","width":772,"height":482,"caption":"pharma-news-for-gilead -otsuka-liquidia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/05\/27162730\/27-05-2025-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epidermolysis Bullosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epidermolysis Bullosa Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IgAN<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IgAN treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Relapsed or Refractory Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Triple-Negative Breast Cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Epidermolysis Bullosa<\/span>","<span class=\"advgb-post-tax-term\">Epidermolysis Bullosa Market<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">IgAN<\/span>","<span class=\"advgb-post-tax-term\">IgAN treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension Drugs<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Relapsed or Refractory Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Triple-Negative Breast Cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 11 months ago","modified":"Updated 9 months ago"},"absolute_dates":{"created":"Posted on May 27, 2025","modified":"Updated on Jul 31, 2025"},"absolute_dates_time":{"created":"Posted on May 27, 2025 4:27 pm","modified":"Updated on Jul 31, 2025 1:02 pm"},"featured_img_caption":"pharma-news-for-gilead -otsuka-liquidia\n","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=32306"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32306\/revisions"}],"predecessor-version":[{"id":32308,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/32306\/revisions\/32308"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/32307"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=32306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=32306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=32306"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=32306"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=32306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}